Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications.

International Journal of Molecular Sciences
Zhenbang Chen, Wenfu Lu

Abstract

The initiation and progression of human prostate cancer are highly associated with aberrant dysregulations of tumor suppressors and proto-oncogenes. Despite that deletions and mutations of tumor suppressors and aberrant elevations of oncogenes at the genetic level are reported to cause cancers, emerging evidence has revealed that cancer progression is largely regulated by posttranslational modifications (PTMs) and epigenetic alterations. PTMs play critical roles in gene regulation, cellular functions, tissue development, diseases, malignant progression and drug resistance. Recent discoveries demonstrate that ubiquitination and SUMOylation are complicated but highly-regulated PTMs, and make essential contributions to diseases and cancers by regulation of key factors and signaling pathways. Ubiquitination and SUMOylation pathways can be differentially modulated under various stimuli or stresses in order to produce the sustained oncogenic potentials. In this review, we discuss some new insights about molecular mechanisms on ubiquitination and SUMOylation, their associations with diseases, oncogenic impact on prostate cancer (PCa) and clinical implications for PCa treatment.

References

Dec 23, 1998·Mechanisms of Ageing and Development·M M ScrofanoA Taylor
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·H PoukkaJ J Palvimo
Aug 15, 2003·Oncogene·Lihong Chen, Jiandong Chen
Aug 4, 2004·Genes & Development·Mei-Ling KuoCharles J Sherr
May 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kenji TagoCharles J Sherr
Jun 16, 2005·Journal of Molecular Endocrinology·H SanttiJ J Palvimo
Dec 6, 2005·Developmental Cell·Karim NacerddineAnne Dejean
Dec 15, 2005·American Journal of Physiology. Endocrinology and Metabolism·Margarita VigodnerPatricia L Morris
Feb 10, 2006·Annals of the New York Academy of Sciences·Xiuping YuRobert J Matusik
May 9, 2006·Nature·Lloyd C TrotmanPier Paolo Pandolfi
May 16, 2006·Nature Cell Biology·Jung Hwa KimSung Hee Baek
Jun 24, 2006·Molecular Cell·Oliver BischofAnne Dejean
Jul 18, 2006·Molecular & Cellular Proteomics : MCP·Karl E Krueger, Sudhir Srivastava
Aug 24, 2006·Neoplasia : an International Journal for Oncology Research·Jinke ChengEdward T H Yeh
Nov 4, 2006·Molecular Cell·Tian Huai ShenPier Paolo Pandolfi
Jan 16, 2007·Cell·Xinjiang WangXuejun Jiang
Jan 16, 2007·Cell·Lloyd C TrotmanPier Paolo Pandolfi
Jan 24, 2007·Lancet·Francis O Walker
May 26, 2007·The Journal of Biological Chemistry·Fang WeiMichael L Atchison
Sep 4, 2007·Cellular and Molecular Life Sciences : CMLS·J Zhao
Oct 13, 2007·The Journal of Biological Chemistry·Tasneem Bawa-KhalfeEdward T H Yeh
Nov 15, 2007·Nature Reviews. Molecular Cell Biology·Ruth Geiss-Friedlander, Frauke Melchior
Dec 1, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yang XiangCharlie Degui Chen
Dec 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jung Hwa KimSung Hee Baek
May 27, 2008·Nature Reviews. Cancer·David Frescas, Michele Pagano
Jul 16, 2008·Molecular and Cellular Biology·Chengzhuo GaoHung-Ying Kao
Dec 6, 2008·The EMBO Journal·Jianxiu YuTomas Mustelin
Mar 14, 2009·Trends in Biochemical Sciences·Kevin D Sarge, Ok-Kyong Park-Sarge
Aug 20, 2009·Science Signaling·Zhenbang ChenPier Paolo Pandolfi
Aug 29, 2009·Science·Wei-Lei YangHui-Kuan Lin
Jan 19, 2010·Cell Cycle·Wei-Lei YangHui-Kuan Lin
Apr 14, 2010·Current Cancer Drug Targets·B WegielJ L Persson

❮ Previous
Next ❯

Citations

Sep 7, 2016·BioData Mining·Nicola LazzariniJaume Bacardit
Jan 27, 2016·Bioorganic & Medicinal Chemistry Letters·Ashutosh KumarKam Y J Zhang
Feb 27, 2020·Cancers·Carla SoléCharles H Lawrie
Feb 26, 2016·Molecular Cancer·Silvia Juliana Serrano-GomezSuresh K Alahari
Jun 14, 2019·Frontiers in Endocrinology·Shehua QianXianquan Zhan
Nov 23, 2019·Cell Communication and Signaling : CCS·Nanyang YangXiaomeng Li
Apr 26, 2020·Proceedings of the National Academy of Sciences of the United States of America·Qiaoyu LinChuanmao Zhang
Aug 19, 2017·Cancer Research·Lin WangBo Han
Feb 15, 2021·The Journal of Steroid Biochemistry and Molecular Biology·Mitzi García-OlivaresDavid Barrera
Mar 13, 2021·Frontiers in Oncology·Zhengfang LiuYidong Fan
May 18, 2021·Genes & Diseases·Mohammad Reza ZinatizadehSeyed Rouhollah Miri
Sep 24, 2021·Nature·Haitham A ElmarakebyEliezer M Van Allen

❮ Previous
Next ❯

Methods Mentioned

BETA
Ubiquitination
deubiquitination

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

Current Gene Therapy
Towia A Libermann, Luiz F Zerbini
Mini Reviews in Medicinal Chemistry
K V DonkenaC Y F Young
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Feng ZhiYilin Yang
Neurochemistry International
Xiao-Qin Zhang, Gilberto Ka-Kit Leung
© 2022 Meta ULC. All rights reserved